A5017059645- Glioma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Neuroblastoma Research and Treatments
- Autoimmune and Inflammatory Disorders Research
- Immunodeficiency and Autoimmune Disorders
- RNA modifications and cancer
- Kawasaki Disease and Coronary Complications
- Systemic Lupus Erythematosus Research
- Brain Metastases and Treatment
- Inflammatory Myopathies and Dermatomyositis
- SARS-CoV-2 and COVID-19 Research
- Esophageal Cancer Research and Treatment
- Esophageal and GI Pathology
- Stoma care and complications
- Childhood Cancer Survivors' Quality of Life
- Neurogenetic and Muscular Disorders Research
- Neurogenesis and neuroplasticity mechanisms
- MRI in cancer diagnosis
- Anorectal Disease Treatments and Outcomes
- Meningioma and schwannoma management
- Advanced Electron Microscopy Techniques and Applications
- ATP Synthase and ATPases Research
- Inflammasome and immune disorders
- Colorectal Cancer Surgical Treatments
- Bacterial Infections and Vaccines
Wilhelmina Children's Hospital
2020-2025
University Medical Center Utrecht
2019-2025
Utrecht University
2002-2024
Amsterdam University Medical Centers
2012-2021
Vrije Universiteit Amsterdam
2014-2021
Emma Kinderziekenhuis
2021
Amsterdam UMC Location Vrije Universiteit Amsterdam
2011-2017
Helios Klinikum Emil von Behring
2011-2017
Hospital Sant Joan de Déu Barcelona
2015
Royal Marsden NHS Foundation Trust
2015
Although diffuse intrinsic pontine glioma (DIPG) carries the worst prognosis of all pediatric brain tumors, studies on prognostic factors in DIPG are sparse. To control for confounding variables studies, which generally include relatively small patient numbers, a survival prediction tool is needed. A multicenter retrospective cohort study was performed Netherlands, UK, and Germany with central review clinical data MRI scans children DIPG. Cox proportional hazards backward regression used to...
Pediatric high-grade gliomas (pHGG), including diffuse intrinsic pontine (DIPG), are the leading cause of cancer-related death in children. While it is clear that surgery (if possible), and radiotherapy beneficial for treatment, role chemotherapy these tumors still unclear. Therefore, we performed an vitro drug screen on primary glioma cells, three DIPG cultures, to determine sensitivity tumours, without possible confounding effect insufficient delivery. This revealed a high cytotoxicity...
Predictive tools for guiding therapy in children with brain tumors are urgently needed. In this first molecular drug imaging study children, we investigated whether bevacizumab can reach diffuse intrinsic pontine glioma (DIPG) by measuring the tumor uptake of 89Zr-labeled PET. addition, evaluated safety procedure and determined optimal time imaging. Methods: Patients received 89Zr-bevacizumab (0.1 mg/kg; 0.9 MBq/kg) at least 2 wk after completing radiotherapy. Whole-body PET/CT scans were...
The role of the VEGF inhibitor bevacizumab in treatment diffuse intrinsic pontine glioma (DIPG) is unclear. We aim to study biodistribution and uptake zirconium-89 ((89)Zr)-labeled DIPG mouse models. Human E98-FM, U251-FM cells, HSJD-DIPG-007-FLUC primary cells were injected into subcutis, pons, or striatum nude mice. Tumor growth was monitored by bioluminescence imaging (BLI) visualized MRI. Seventy-two 96 hours after (89)Zr-bevacizumab injections, mice imaged positron emission tomography...
JDM is a rare chronic immune-mediated inflammatory disease with predominant role for type I IFN responses. We aimed to determine the potential of Siglec-1 expression on monocytes as novel IFN-inducible biomarker activity monitoring and prediction treatment response in patients JDM.Siglec-1 was measured by flow cytometry circulating 21 newly diagnosed before start and, 10 these, also during follow-up. The levels five IFN-stimulated genes, MX1, IFI44, IFI44L, LY6E IFIT3, were RT-qPCR signature...
Objective Human leukocyte antigen (HLA)‐DRB1*15:01 has been recently associated with interstitial lung disease (LD), eosinophilia, and drug reactions in systemic juvenile idiopathic arthritis (sJIA). Additionally, genetic variants IL1RN have linked to poor response anakinra. We sought reproduce these findings a prospective cohort study of patients new‐onset sJIA treated anakinra as first‐line therapy. Methods HLA risk alleles were identified via whole‐genome sequencing. Treatment responses...
The aim of this study was to analyze the early postoperative outcome esophageal cancer treated by subtotal resection, gastric interposition and either intrathoracic or cervical anastomosis in a single center study. 72 patients who received after resection for were matched age tumor stage. Collected data from these analyzed retrospectively regarding morbidity mortality rates. Anastomotic leakage rate significantly lower group than (4 36 (11%) vs. 11 (31%); p = 0.040). hospital stay shorter...
Janus kinase inhibition (JAKi) has been proposed as a treatment for idiopathic inflammatory myopathies to target increased interferon signalling. Predominantly retrospective reports have demonstrated effectiveness of JAKi in refractory juvenile dermatomyositis (JDM). However, remains an off-label JDM and there may be variation use worldwide. An international survey was conducted investigate approaches JDM. The Childhood Arthritis Rheumatology Research Alliance (CARRA) Therapeutics workgroup...
Abstract Introduction This study investigates the safety, tolerability, and preliminary efficacy of combined treatment with VEGF inhibitor bevacizumab, topoisomerase I irinotecan, EGFR erlotinib in children progressive diffuse intrinsic pontine glioma (DIPG). Methods Biweekly bevacizumab (10 mg/kg) irinotecan (125 mg/m 2 ) were daily erlotinib. Two cohorts received increasing doses (65 85 following a 3 + dose-escalation schedule, until disease progression maximum one year. Dose-limiting...
Mutations in the common gamma chain (γc, CD132, encoded by IL2RG gene) can lead to B+T−NK− X-linked severe combined immunodeficiency, as a consequence of unresponsiveness γc-cytokines such interleukins-2, -7 and -15. Hypomorphic mutations CD132 may cause immunodeficiencies with variety clinical presentations. We analyzed peripheral blood mononuclear cells 6-year-old boy normal lymphocyte counts, who suffered from recurrent pneumonia disseminated mollusca contagiosa. Since proliferative...
More than 90% of patients with diffuse intrinsic pontine glioma (DIPG) will die within 2 years diagnosis. Patients deteriorate rapidly during the disease course, which severely impairs their quality life. To date, no specific research on this clinically important subject has been conducted. This study aimed to compile an inventory symptoms experienced, interventions applied, and current service provision in end-of-life care for DIPG. We performed a retrospective cohort children DIPG, aged...
Diffuse intrinsic pontine glioma (DIPG) is a fatal paediatric malignancy. Tumour resection not possible without serious morbidity and biopsies are rarely performed. The resulting lack of primary DIPG material has made preclinical research practically impossible hindered the development new therapies for this disease. aim current study was to address models by developing multi-institutional autopsy protocol.An protocol implemented in Netherlands obtain tumour within brief post mortem...
We aimed to perform external validation of the recently developed survival prediction model for diffuse intrinsic pontine glioma (DIPG), and discuss its utility. The DIPG was in a cohort patients from Netherlands, United Kingdom Germany, registered SIOPE Registry, includes age <3 years, longer symptom duration receipt chemotherapy as favorable predictors, presence ring-enhancement on MRI unfavorable predictor. Model performance evaluated by analyzing discrimination calibration abilities....